Initial Ten Years of Experience with the Intravitreal Dexamethasone Implant: A Retrospective Chart Review
Josh Wallsh,1 Charlotte Luths,2 Haily Kil,2 Ron Gallemore2 1Albany Medical Center, Department of Ophthalmology, Albany, NY, USA; 2Retina Macula Institute and Research Center, Torrance, CA, USACorrespondence: Ron GallemoreRetina Macula Institute and Research Center, 4201 Torrance Blvd Suite 220, Torr...
Guardado en:
Autores principales: | , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ac45a16b8e0d45e8b1001795fc25cce5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:ac45a16b8e0d45e8b1001795fc25cce5 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:ac45a16b8e0d45e8b1001795fc25cce52021-12-02T13:00:15ZInitial Ten Years of Experience with the Intravitreal Dexamethasone Implant: A Retrospective Chart Review1177-5483https://doaj.org/article/ac45a16b8e0d45e8b1001795fc25cce52020-10-01T00:00:00Zhttps://www.dovepress.com/initial-ten-years-of-experience-with-the-intravitreal-dexamethasone-im-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Josh Wallsh,1 Charlotte Luths,2 Haily Kil,2 Ron Gallemore2 1Albany Medical Center, Department of Ophthalmology, Albany, NY, USA; 2Retina Macula Institute and Research Center, Torrance, CA, USACorrespondence: Ron GallemoreRetina Macula Institute and Research Center, 4201 Torrance Blvd Suite 220, Torrance, CA 90503, USAEmail rongallemoremd@gmail.comPurpose: To evaluate the initial ten years of results from the intravitreal dexamethasone implant (DEX) in patients treated for retinal vein occlusion (RVO), diabetic macular edema (DME) or uveitis.Methods: Retrospective chart review of patients receiving DEX since its FDA approval. Best-corrected visual acuity (BCVA), central macular thickness (CMT) on optical coherence tomography, intraocular pressure and cataract status were collected. Baseline data were collected from the initial DEX and post-treatment data at the visit at least four weeks after the last DEX.Results: In total, 315 eyes received 1216 DEX over 63.9± 4.6 weeks. In the branch RVO (n=90), central RVO (n=59) and DME (n=62) cohorts, BCVA improved significantly (p< 0.05). The uveitis (n=154) cohort did not have a significant change in BCVA, 0.62± 0.04 to 0.61± 0.04 logMAR (p=0.34). Younger patients, vitrectomized eyes, and eyes without a history of glaucoma were associated with significantly better BCVA outcomes in the uveitis cohort (p< 0.05). Overall, CMT decreased significantly from 376.6± 6.8 to 322.7± 5.0 μm (p< 0.05). Intraocular pressure increased significantly (p< 0.001) and the percentage of patients requiring anti-glaucoma medications increased from 33.0% to 67.6%. Of phakic eyes, 58.8% (n=63) had cataract progression or underwent surgery with those who underwent surgery experiencing a significant improvement in BCVA (p< 0.05).Conclusion: Repeated DEX over extended follow-up offers significant anatomic benefits to all cohorts. Visual benefits are only seen in RVO, DME and select uveitis demographics.Keywords: uveitis, branch retinal vein occlusion, central retinal vein occlusion, diabetic macular edema, dexamethasone implantWallsh JLuths CKil HGallemore RDove Medical Pressarticleuveitisbranch retinal vein occlusioncentral retinal vein occlusiondiabetic macular edemadexamethasone implantOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 14, Pp 3097-3108 (2020) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
uveitis branch retinal vein occlusion central retinal vein occlusion diabetic macular edema dexamethasone implant Ophthalmology RE1-994 |
spellingShingle |
uveitis branch retinal vein occlusion central retinal vein occlusion diabetic macular edema dexamethasone implant Ophthalmology RE1-994 Wallsh J Luths C Kil H Gallemore R Initial Ten Years of Experience with the Intravitreal Dexamethasone Implant: A Retrospective Chart Review |
description |
Josh Wallsh,1 Charlotte Luths,2 Haily Kil,2 Ron Gallemore2 1Albany Medical Center, Department of Ophthalmology, Albany, NY, USA; 2Retina Macula Institute and Research Center, Torrance, CA, USACorrespondence: Ron GallemoreRetina Macula Institute and Research Center, 4201 Torrance Blvd Suite 220, Torrance, CA 90503, USAEmail rongallemoremd@gmail.comPurpose: To evaluate the initial ten years of results from the intravitreal dexamethasone implant (DEX) in patients treated for retinal vein occlusion (RVO), diabetic macular edema (DME) or uveitis.Methods: Retrospective chart review of patients receiving DEX since its FDA approval. Best-corrected visual acuity (BCVA), central macular thickness (CMT) on optical coherence tomography, intraocular pressure and cataract status were collected. Baseline data were collected from the initial DEX and post-treatment data at the visit at least four weeks after the last DEX.Results: In total, 315 eyes received 1216 DEX over 63.9± 4.6 weeks. In the branch RVO (n=90), central RVO (n=59) and DME (n=62) cohorts, BCVA improved significantly (p< 0.05). The uveitis (n=154) cohort did not have a significant change in BCVA, 0.62± 0.04 to 0.61± 0.04 logMAR (p=0.34). Younger patients, vitrectomized eyes, and eyes without a history of glaucoma were associated with significantly better BCVA outcomes in the uveitis cohort (p< 0.05). Overall, CMT decreased significantly from 376.6± 6.8 to 322.7± 5.0 μm (p< 0.05). Intraocular pressure increased significantly (p< 0.001) and the percentage of patients requiring anti-glaucoma medications increased from 33.0% to 67.6%. Of phakic eyes, 58.8% (n=63) had cataract progression or underwent surgery with those who underwent surgery experiencing a significant improvement in BCVA (p< 0.05).Conclusion: Repeated DEX over extended follow-up offers significant anatomic benefits to all cohorts. Visual benefits are only seen in RVO, DME and select uveitis demographics.Keywords: uveitis, branch retinal vein occlusion, central retinal vein occlusion, diabetic macular edema, dexamethasone implant |
format |
article |
author |
Wallsh J Luths C Kil H Gallemore R |
author_facet |
Wallsh J Luths C Kil H Gallemore R |
author_sort |
Wallsh J |
title |
Initial Ten Years of Experience with the Intravitreal Dexamethasone Implant: A Retrospective Chart Review |
title_short |
Initial Ten Years of Experience with the Intravitreal Dexamethasone Implant: A Retrospective Chart Review |
title_full |
Initial Ten Years of Experience with the Intravitreal Dexamethasone Implant: A Retrospective Chart Review |
title_fullStr |
Initial Ten Years of Experience with the Intravitreal Dexamethasone Implant: A Retrospective Chart Review |
title_full_unstemmed |
Initial Ten Years of Experience with the Intravitreal Dexamethasone Implant: A Retrospective Chart Review |
title_sort |
initial ten years of experience with the intravitreal dexamethasone implant: a retrospective chart review |
publisher |
Dove Medical Press |
publishDate |
2020 |
url |
https://doaj.org/article/ac45a16b8e0d45e8b1001795fc25cce5 |
work_keys_str_mv |
AT wallshj initialtenyearsofexperiencewiththeintravitrealdexamethasoneimplantaretrospectivechartreview AT luthsc initialtenyearsofexperiencewiththeintravitrealdexamethasoneimplantaretrospectivechartreview AT kilh initialtenyearsofexperiencewiththeintravitrealdexamethasoneimplantaretrospectivechartreview AT gallemorer initialtenyearsofexperiencewiththeintravitrealdexamethasoneimplantaretrospectivechartreview |
_version_ |
1718393587767443456 |